Skip to main content
. Author manuscript; available in PMC: 2021 Aug 26.
Published in final edited form as: Exp Gerontol. 2021 Apr 10;150:111343. doi: 10.1016/j.exger.2021.111343

Table 3.

Adjusteda 400-m walking speed and SPPB score at each follow-up time, by metabolic syndrome (MetS) status and intervention group.

Non-MetS MetS




PA HE PA HE






Mean (SE) Mean (SE) P-value (for difference PA-HE) Mean (SE) Mean (SE) P-value (for difference PA-HE)
400-m walking speed (m/s)baseline 0.84 (0.01) 0.84 (0.01) 0.96 0.81 (0.01) 0.80 (0.01) 0.15
 6 months 0.85 (0.01) 0.83 (0.01) 0.03 0.85 (0.01) 0.81 (0.01) <0.001
 12 months 0.82 (0.01) 0.81 (0.01) 0.53 0.82 (0.01) 0.79 (0.01) <0.001
 18 months 0.81 (0.01) 0.80 (0.01) 0.42 0.81 (0.01) 0.77 (0.01) <0.001
 24 months 0.79 (0.01) 0.78 (0.01) 0.64 0.79 (0.01) 0.75 (0.01) <0.001
 30 months 0.75 (0.01) 0.76 (0.01) 0.50 0.77 (0.01) 0.74 (0.01) 0.03
 36 months 0.74 (0.01) 0.75 (0.01) 0.41 0.75 (0.01) 0.73 (0.01) 0.24
 42 months 0.73 (0.02) 0.76 (0.02) 0.30 0.74 (0.02) 0.68 (0.01) 0.01
Overall effectb 0.91 <0.001
P-value for interactionc = 0.07
SPPB scored baseline 7.37 (0.08) 7.44 (0.08) 0.55 7.45 (0.08) 7.23 (0.08) 0.06
 6 months 8.50 (0.11) 8.21 (0.11) 0.06 8.46 (0.11) 8.10 (0.11) 0.02
 12 months 8.20 (0.11) 8.06 (0.11) 0.33 8.46 (0.11) 8.05 (0.11) 0.01
 24 months 7.92 (0.11) 7.78 (0.11) 0.34 7.96 (0.11) 7.75 (0.11) 0.18
 36 months 7.75 (0.15) 7.48 (0.15) 0.21 7.68 (0.15) 7.70 (0.15) 0.92
Overall effectb 0.11 0.07
P-value for interactionc = 0.22

Abbreviations: MetS – metabolic syndrome; PA – physical activity; HE – health education; SPPB – Short Physical Performance Battery.

a

Adjusted for clinical site and gender.

b

Overall difference in 400-m walk speed and SPPB across follow-up time points, adjusted for baseline value.

c

Interaction terms included MetS * intervention group, MetS * time, intervention group * time, and MetS * group * time terms.

d

Per inclusion criteria, participants were eligible if they had a baseline SPPB score of 9 or less; SPPB scores could potentially be >9 at follow-up visits.